Related Experiment Video
Updated: Jul 8, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort
Megan R W Barber1, John G Hanly2, Li Su3
1University of Calgary, Alberta, Canada.
Arthritis Care & Research
|December 2, 2017
Summary
Lupus nephritis significantly increases long-term healthcare costs, with severe kidney damage leading to 15-fold higher expenses. Understanding disease severity is crucial for evaluating new lupus nephritis treatments.
Area of Science:
- Nephrology
- Rheumatology
- Health Economics
Background:
- Long-term healthcare costs associated with lupus nephritis (LN) are not well understood.
- Lupus nephritis is a serious complication of systemic lupus erythematosus affecting the kidneys.
Purpose of the Study:
- To compare the long-term costs of patients with and without lupus nephritis.
- To utilize multistate modeling to predict 10-year cumulative costs based on renal function and disease severity.
Main Methods:
- A cohort of 1,545 patients from 32 centers in 11 countries were followed for a mean of 6.3 years.
- Renal function was assessed annually via estimated glomerular filtration rate (GFR) or proteinuria.
- A multistate model was employed to estimate 10-year cumulative costs for different renal states.
Main Results:
- Lupus nephritis developed in 39.4% of the study participants.
- Ten-year cumulative costs were substantially higher for patients with LN and impaired renal function (e.g., GFR <30 ml/minute or proteinuria >3 gm/day) compared to those without LN.
- Patients with GFR <30 ml/minute incurred 15-fold higher 10-year costs than those with normal GFR.
Conclusions:
- Disease severity at presentation is a key factor in anticipating future healthcare costs for lupus nephritis patients.
- This cost data is vital for assessing the cost-effectiveness of novel therapeutic interventions for lupus nephritis.
- Multistate modeling provides a framework for predicting long-term economic burden in chronic kidney diseases.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
488
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
488
01:07Determination of Renal Drug Clearance: Graphical and Midpoint Methods
419
Renal clearance, a crucial parameter in pharmacokinetics, can be determined using two different methods: the graphical method and the midpoint method. These methods provide insights into the rate of drug excretion by the kidneys and aid in assessing renal function.
The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a...
The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a...
419
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
248
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
248
01:24Nephrotic Syndrome I : Introduction
705
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
705
01:26Nephrotic Syndrome II : Assessment and Medical Management
257
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
257
01:24Nephrotic Syndrome III : Nursing Management
358
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
358